Compare RGP & SGMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGP | SGMO |
|---|---|---|
| Founded | 1996 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.8M | 141.2M |
| IPO Year | 2000 | 2000 |
| Metric | RGP | SGMO |
|---|---|---|
| Price | $3.77 | $0.45 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $6.00 | $5.75 |
| AVG Volume (30 Days) | 463.9K | ★ 8.1M |
| Earning Date | 04-06-2026 | 05-11-2026 |
| Dividend Yield | ★ 7.59% | N/A |
| EPS Growth | N/A | ★ 66.89 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $551,331,000.00 | $36,567,000.00 |
| Revenue This Year | N/A | $4.79 |
| Revenue Next Year | $1.49 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 88.60 |
| 52 Week Low | $3.42 | $0.35 |
| 52 Week High | $7.41 | $1.06 |
| Indicator | RGP | SGMO |
|---|---|---|
| Relative Strength Index (RSI) | 38.43 | 55.11 |
| Support Level | N/A | $0.43 |
| Resistance Level | $4.86 | $0.48 |
| Average True Range (ATR) | 0.18 | 0.04 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 36.41 | 46.41 |
Resources Connection Inc provides consulting and business initiative support services predominantly through its operative subsidiary, Resources Global Professionals. It has two segments RGP ( Resources Global Professionals.) and Sitrick. The RGP segment is focused on delivering consulting services catering to its client's operational needs and change initiatives utilizing a combination of bench and on-demand, talent. The Sitrick segment provides corporate, financial, transactional, and crisis communication and management services. The company generates a majority of its revenue from the RGP segment. Geographically, it derives its key revenue from North America and the rest from Europe and the Asia Pacific region.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.